Drug Trial Radar · NCT00067457
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
Last checked: Nov 19, 2026Latest source record: Apr 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
700
Actual
Start
Jun 2003
Primary completion
Dec 2005
Study completion Dec 2005
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 21, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and effectiveness of as needed versus fixed dosing of an investigational medication for women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.
Conditions
- Irritable Colon
- Irritable Bowel Syndrome (IBS)
Interventions
alosetronDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities.Time frame: 12 Weeks
Locations
191 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Pell City, Alabama
GSK Investigational Site
Tallassee, Alabama
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
North Little Rock, Arkansas
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Carlsbad, California
GSK Investigational Site
Concord, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Garden Grove, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Orange, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
Santa Ana, California
GSK Investigational Site
Spring Valley, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Van Nuys, California
GSK Investigational Site
Centennial, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Littleton, Colorado
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Bristol, Connecticut
GSK Investigational Site
Belleair Bluffs, Florida
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Bradenton, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
DeLand, Florida
GSK Investigational Site
Gainesville, Florida
Showing 40 of 191 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.